Advertisement

The Cerebellum

, Volume 13, Issue 1, pp 178–183 | Cite as

Leukoencephalopathy due to Oral Methotrexate

  • I. González-Suárez
  • M. J. Aguilar-Amat
  • M. Trigueros
  • A. M. Borobia
  • A. Cruz
  • J. Arpa
Review

Abstract

Methotrexate (MTX) is considered the main agent for the treatment of rheumatoid arthritis (RA). Neurotoxicity is often mild, but severe encephalopathy can develop, especially with intrathecal or intravenous administration. In rare cases, this syndrome has been observed in patients on long-term low-dose oral administration. A 68-year-old male was diagnosed with RA and on treatment with oral MTX 25 mg weekly for 4 years. The patient started with progressive dysarthria, ataxia and cognitive dysfunction. Complementary tests were normal. Magnetic resonance imaging (MRI) showed hyperintense lesions in both cerebellar hemispheres on T2-weighted and FLAIR images with a diffusion restriction on diffusion-weighted imaging (DWI) and on the apparent diffusion coefficient map (ADC). On postgadolinium T1-weighted images, there were mild enhancements. Spectroscopy showed a demyelinating pattern. A pharmacogenetics determination was made, showing a heterozygous genotype in the MTHFR and ABCB1 genes. Medication with antirheumatic drug was stopped immediately on admission, and the patient gradually improved. MTX-induced leukoencephalopathy can occur even with low-dose administration. The exact pathogenic mechanism is still unknown, but it is hypothesised that it could be the result of a cumulative toxic effect on the blood–brain barrier. The nature of the relationship between the polymorphism and CNS toxicity is still unclear, and thus, further studies are warranted. Often located in the occipital lobes, the involvement of the cerebellum is quite rare. Early recognition of the condition and withdrawal of the drug lead to a better prognosis.

Keywords

MTX leukoencephalopathy MTX polymorphisms Toxic cerebellopathy MTHFR C677T toxicity 

Notes

Conflicts of Interest

There are no conflicts of interest in this manuscript.

References

  1. 1.
    Smolen JS, Landewé R, Breedveld FC, Dougados M, Emery P, Gaujoux-Viala C, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis. 2010;69:964.PubMedCentralPubMedCrossRefGoogle Scholar
  2. 2.
    Weiss HD, Walker MD, Wiernik PH. Neurotoxicity of commonly used antineoplastic agents (first of two parts). N Engl J Med. 1974;291:75–81.PubMedCrossRefGoogle Scholar
  3. 3.
    Weinblatt ME. Toxicity of low dose methotrexate in rheumatoid arthritis. J Rheumatol. 1983;12:35–9.Google Scholar
  4. 4.
    Wernick R, Smith DL. Central nervous system toxicity associated with weekly low-dose methotrexate treatment. Arthritis Rheum. 1989;32:770–5.PubMedCrossRefGoogle Scholar
  5. 5.
    Lovblad K, Kelkar P, Ozdoba C, Ramelli G, Remonda L, Schroth G. Pure methotrexate encephalopathy presenting with seizures: CT and MRI features. Pediatr Radiol. 1998;28:86–91.PubMedCrossRefGoogle Scholar
  6. 6.
    Mahoney Jr DH, Shuster JJ, Nitschke R, Lauer SJ, Steuber CP, Winick N, et al. Acute neurotoxicity in children with B-precursor acute lymphoid leukemia: an association with intermediate-dose intravenous methotrexate and intrathecal triple therapy—a Pediatric Oncology Group study. J Clin Oncol. 1998;16:1712–22.PubMedGoogle Scholar
  7. 7.
    García-Puig M, Fons-Estupiña MC, Rives-Solà S, Berrueco-Moreno R, Cruz-Martínez O, Campisto J. Neurotoxicity due to methotrexate in paediatric patients. Description of the clinical symptoms and neuroimaging findings. Rev Neurol. 2012;54:712–8.PubMedGoogle Scholar
  8. 8.
    Salkade PR, Lim TA. Methotrexate-induced acute toxic leukoencephalopathy. J Cancer Res Ther. 2012;8:292–6.PubMedCrossRefGoogle Scholar
  9. 9.
    Worthley S, McNeil J. Leukoencephalopathy in a patient taking low dose oral methotrexate therapy for rheumatoid arthritis. J Rheumatol. 1995;22:335–7.PubMedGoogle Scholar
  10. 10.
    Renard D, Westhovens R, Vandenbussche E, Vandenberghe R. Reversible posterior leukoencephalopathy during oral treatment with methotrexate. J Neurol. 2004;251:226–8.PubMedCrossRefGoogle Scholar
  11. 11.
    Yokoo H, Nakazato Y, Harigaya Y, Sasaki N, Igata Y, Itoh H. Massive myelinolytic leukoencephalopathy in a patient medicated with low-dose oral methotrexate for rheumatoid arthritis: an autopsy report. Acta Neuropathol. 2007;114:425–30.PubMedCrossRefGoogle Scholar
  12. 12.
    Raghavendra S, Nair MD, Chemmanam T, Krishnamoorthy T, Radhakrishnan VV, Kuruvilla A. Disseminated necrotizing leukoencephalopathy following low-dose oral methotrexate. Eur J Neurol. 2007;14:309–14.PubMedCrossRefGoogle Scholar
  13. 13.
    Marcon G, Giovagnoli AR, Mangiopane P, Erbetta A, Tagliavini F, Girotti F. Regression of chronic posterior leukoencephalopathy after stop of methotrexate treatment. Neurol Sci. 2009;30:375–8.PubMedCrossRefGoogle Scholar
  14. 14.
    Matsuda M, Kishida D, Kinoshita T, Hineno A, Shimojima Y, Fukushima K, et al. Leukoencephalopathy induced by low-dose methotrexate in a patient with rheumatoid arthritis. Intern Med. 2011;50(19):2219–22.PubMedCrossRefGoogle Scholar
  15. 15.
    Hart C, Kinney MO, McCarron MO. Posterior reversible encephalopathy syndrome and oral methotrexate. Clin Neurol Neurosurg. 2012;114:725–7.PubMedCrossRefGoogle Scholar
  16. 16.
    Koppen H, Wessels JA, Ewals JAPM, Treurniet FEE. Reversible leukoencephalopathy after oral methotrexate. J Rheumatol. 2012;39:1906–7.PubMedCrossRefGoogle Scholar
  17. 17.
    Manto M. Toxic agents causing cerebellar ataxia. Handb Clin Neurol. 2012;103:201–13.PubMedCrossRefGoogle Scholar
  18. 18.
    Bernini JC, Fort DW, Griener JC, et al. Aminophylline for methotrexate-induced neurotoxicity. Lancet. 1995;345:544–7.PubMedCrossRefGoogle Scholar
  19. 19.
    Drachtman RA, Cole PD, Golden CB, James SJ, Melnyk S, Aisner J, et al. Dextromethorphan is effective in the treatment of subacute methotrexate neurotoxicity. Pediatr Hematol Oncol. 2002;19:319–27.PubMedCrossRefGoogle Scholar
  20. 20.
    Linnebank M, Pels H, Kleczar N, Farmand S, Fliessbach K, Urbach H, et al. MTX-induced white matter changes are associated with polymorphisms of methionine metabolism. Neurology. 2005;64:912–91.PubMedCrossRefGoogle Scholar
  21. 21.
    Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG, et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet. 1995;10:111–3.PubMedCrossRefGoogle Scholar
  22. 22.
    Quinn CT, Kamen BA. A biochemical perspective of methotrexate neurotoxicity within sight on non folate rescue modalities. J Investig Med. 1996;44:522–30.PubMedGoogle Scholar
  23. 23.
    Strunk T, Gottschalk S, Goepel W, Bucsky P, Schultz C. Subacute leukoencephalopathy after low-dose intrathecal methotrexate in an adolescent heterozygous for the MTHFRC677T polymorphism. Med Pediatr Oncol. 2003;40:48–50.PubMedCrossRefGoogle Scholar
  24. 24.
    Weisman MH, Furst DE, Park GS, Kremer JM, Smith KM, Wallace DJ, et al. Risk genotypes in folate-dependent enzymes and their association with methotrexate-related side effects in rheumatoid arthritis. Arthritis Rheum. 2006;54:607–12.PubMedCrossRefGoogle Scholar
  25. 25.
    Fisher M, Cronstein BN. Meta-analysis of methylenetetrahydrofolate reductase (MTHFR) polymorphisms affecting methotrexate toxicity. Rheumatol. 2009;36:539–45.Google Scholar
  26. 26.
    Treviño LR, Shimasaki N, Yang W, Panetta JC, Cheng C, Pei D, et al. Germline genetic variation in an organic anion transporter polypeptide associated with methotrexate pharmacokinetics and clinical effects. J Clin Oncol. 2009;27(35):5972–8.PubMedCrossRefGoogle Scholar
  27. 27.
    Takatori R, Takahashi KA, Tokunaga D, et al. ABCB1 C3435T polymorphism influences methotrexate sensitivity in rheumatoid arthritis patients. Clin Exp Rheumatol. 2006;24:546–54.PubMedGoogle Scholar
  28. 28.
    Hinchey J, Chaves C, Appignani B, Breen J, Pao L, Wang A, et al. A reversible posterior leukoencephalopathy syndrome. N Engl J Med. 1996;334:494–500.PubMedCrossRefGoogle Scholar
  29. 29.
    Oka M, Terae S, Kobayashi R, Sawamura Y, Kudoh K, Tha KK, et al. MRI in methotrexate-related leukoencephalopathy: disseminated necrotizing leukoencephalopathy in comparison with mild leukoencephalopathy. Neuroradiology. 2003;45:493–7.Google Scholar
  30. 30.
    Eichler FS, Wang P, Wityk RJ, Beauchamp Jr NJ, Barker PB. Diffuse metabolic abnormalities in reversible posterior leukoencephalopathy syndrome. AJNR. 2002;23:833–7.Google Scholar
  31. 31.
    Saindane AM, Cha S, Law M, Xue X, Knopp EA, Zagzag D. Proton MR spectroscopy of tumefactive demyelinating lesions. AJNR Am J Neuroradiol. 2002;23:1378–86.Google Scholar
  32. 32.
    Walker DH, Gear JH. Correlations of the distribution of Rickettsia conorii, microscopic lesions, and clinical features in South Africans tick bite fever. Am J Trop Med Hyg. 1985;34:361–71.Google Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • I. González-Suárez
    • 1
  • M. J. Aguilar-Amat
    • 1
  • M. Trigueros
    • 2
  • A. M. Borobia
    • 3
  • A. Cruz
    • 1
  • J. Arpa
    • 1
  1. 1.Department of Neurology, IdiPAZHealth Research InstituteLa Paz University Hospital, School of Medicine, Universidad Autónoma de MadridMadridSpain
  2. 2.Department of Internal MedicineLa Paz University Hospital, School of Medicine, Universidad Autónoma de MadridMadridSpain
  3. 3.Clinical Pharmacology ServiceLa Paz University Hospital, School of Medicine, Universidad Autónoma de MadridMadridSpain

Personalised recommendations